StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.77−0.09 (-2.33%)

Close on Nov 18, 2026Market cap $184.32MP/E –Yield –

Artiva Biotherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Artiva Biotherapeutics's revenue for the twelve months ending Dec 31, 2024 was $251.00K, down 99.3% year over year. For fiscal 2025 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$251.00K-99.3%
FY2023Dec 31, 2023$33.49M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$251.00K–
Q4 FY2023Dec 31, 2023$2.35M–
Q3 FY2023Sep 30, 2023$26.66M–
Q2 FY2023Jun 30, 2023$3.50M–

More Artiva Biotherapeutics figures

See a number that looks wrong?